AVNS (Avanos Medical) 10-Year RORE % : 29.23% (As of Mar. 2026)


AVNS Avanos Medical Inc AVNS
62 GF Score
Price $24.93
GF Value $19.39
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Avanos Medical 10-Year RORE %?

Avanos Medical AVNS -0.04% 62 10-Year RORE % is 29.23 as of Mar. 2026. GuruFocus rates AVNS with a GF Score™ of 62/100 and a GF Value™ of $19.39 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 428 Medical Devices & Instruments companies, Avanos Medical ranks better than 85.98% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Avanos Medical's 10-Year RORE % for the quarter that ended in Mar. 2026 was 29.23%.

The industry rank for Avanos Medical's 10-Year RORE % or its related term are showing as below:

AVNS's 10-Year RORE % is ranked better than
85.98% of 428 companies
in the Medical Devices & Instruments industry
Industry Median: 0.735 vs AVNS: 29.23

Avanos Medical  (NYSE:AVNS) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Avanos Medical 10-Year RORE % Related Terms


Avanos Medical 10-Year RORE % Historical Data

* Premium members only.

The historical data trend for Avanos Medical's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avanos Medical 10-Year RORE % Chart

Avanos Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 118.41 29.04 -4.02 29.91

Avanos Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.94 4.04 143.61 29.91 29.23

AVNS vs LMRI, AORT, IRMD: 10-Year RORE % Comparison

For the Medical Devices subindustry, Avanos Medical's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avanos Medical 10-Year RORE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Avanos Medical's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Avanos Medical's 10-Year RORE % falls into.


AVNS
62GF Score
Avanos Medical Inc AVNS
10-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avanos Medical 10-Year RORE % Calculation

Avanos Medical's 10-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( -1.61-0.81 )/( -8.28-0 )
=-2.42/-8.28
=29.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 10-year before.

Frequently Asked Questions Learn more about 10-Year RORE % →
What does a 10-Year RORE % of 29.23 mean?
Avanos Medical (AVNS) has a 10-Year RORE % of 29.23 as of Mar. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Avanos Medical and its competitors. According to the industry distribution chart, Avanos Medical ranks #60 out of 428 companies in the Medical Devices & Instruments industry, placing it in the top 14%.
Is Avanos Medical's 10-Year RORE % too high?
Avanos Medical's current 10-Year RORE % is 29.23. The Medical Devices & Instruments industry median 10-Year RORE % is 0.74. Avanos Medical's value of 29.23 is 3876.9% above this industry median. Based on the distribution chart, Avanos Medical ranks #60 out of 428 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Avanos Medical has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avanos Medical's 10-Year RORE % compare to LMRI and AORT?
According to the Medical Devices & Instruments industry distribution chart, Avanos Medical ranks #60 out of 428 companies for 10-Year RORE %. This places Avanos Medical in the top 14% of its industry — outperforming the majority of peers. The industry median 10-Year RORE % is 0.74. Avanos Medical's value of 29.23 is 3876.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Medical Devices & Instruments company?
The median 10-Year RORE % among Medical Devices & Instruments companies is 0.74, based on 428 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avanos Medical's current 10-Year RORE % of 29.23 is 3876.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Avanos Medical and its competitors. For the Medical Devices & Instruments industry, the median 10-Year RORE % is 0.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avanos Medical's current 10-Year RORE % is 29.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avanos Medical stock overvalued right now?
Based on GuruFocus' analysis, Avanos Medical (AVNS) is currently considered Modestly Overvalued. The stock's GF Value™ is $19.39, compared to a current price of $24.93 — trading 28.6% above its estimated fair value. The current 10-Year RORE % is 29.23 and 3876.9% above the Medical Devices & Instruments industry median of 0.74. Avanos Medical's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Avanos Medical (AVNS), the current 10-Year RORE % is 29.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Avanos Medical (AVNS) Overvalued in 2026?

Based on GuruFocus' analysis, Avanos Medical stock appears to be overvalued. The current stock price of $24.93 is trading 28.6% above its estimated GF Value™ of $19.39. GuruFocus considers Avanos Medical to be Modestly Overvalued.

Key valuation signals for AVNS:

  • 10-Year RORE %: 29.23
  • GF Value™: $19.39 vs. price of $24.93 (28.6% above fair value)
  • GF Score™: 62/100 with 5 warning signs
  • Industry Position: 3876.9% above the Medical Devices & Instruments median (#60 of 428)

No single metric tells the full story. See the AVNS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Avanos Medical Business Description

Address 5405 Windward Parkway, Suite 100 South, Alpharetta, GA, USA, 30004
Avanos Medical Inc is a medical technology company engaged in the development and commercialization of products for pain management and patient care. The company has two reportable segments: Specialty Nutrition Systems and Pain Management and Recovery. The Specialty Nutrition Systems segment provides enteral feeding and neonatal products. The Pain Management and Recovery segment offers surgical pain and recovery products, including pain pumps and radiofrequency ablation solutions for the treatment of chronic pain.
62GF Score

Get the complete analysis for AVNS

10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.93
Price
$19.39
GF Value